About: Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice
Creator	Subbarao, Kanta Vogel, Leatrice Roberts, Anjeanette Luzuriaga, Katherine Somasundaran, Mohan Thomas, William Greenough, Thomas Ambrosino, Donna Finberg, Robert Sullivan, John Babcock, Gregory Coccia, Jennifer Graziano, Robert Hernandez, Hector Lowy, Israel Srinivasan, Mohan
Source	Medline; PMC
abstract	Background. Severe acute respiratory syndrome (SARS) remains a significant public health concern after the epidemic in 2003. Human monoclonal antibodies (MAbs) that neutralize SARS-associated coronavirus (SARSCoV) could provide protection for exposed individuals. Methods. Transgenic mice with human immunoglobulin genes were immunized with the recombinant major surface (S) glycoprotein ectodomain of SARS-CoV. Epitopes of 2 neutralizing MAbs derived from these mice were mapped and evaluated in a murine model of SARS-CoV infection. Results. Both MAbs bound to S glycoprotein expressed on transfected cells but differed in their ability to block binding of S glycoprotein to Vero E6 cells. Immunoprecipitation analysis revealed 2 antibody-binding epitopes: one MAb (201) bound within the receptor-binding domain at aa 490–510, and the other MAb (68) bound externally to the domain at aa 130–150. Mice that received 40 mg/kg of either MAb prior to challenge with SARS-CoV were completely protected from virus replication in the lungs, and doses as low as 1.6 mg/kg offered significant protection. Conclusions. Two neutralizing epitopes were defined for MAbs to SARS-CoV S glycoprotein. Antibodies to both epitopes protected mice against SARS-CoV challenge. Clinical trials are planned to test MAb 201, a fully human MAb specific for the epitope within the receptor-binding region.
has issue date	2005-02-15(xsd:dateTime)
bibo:doi	10.1086/427242
bibo:pmid	15655773
has license	no-cc
sha1sum (hex)	91e8110a78535c9a7c438219cc93011a17c68c62
schema:url	https://doi.org/10.1086/427242
resource representing a document's title	Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice
has PubMed Central identifier	PMC7110081
has PubMed identifier	15655773
schema:publication	J Infect Dis
resource representing a document's body	covid:91e8110a78535c9a7c438219cc93011a17c68c62#body_text
is schema:about of	named entity 'Human' named entity '2005' named entity 'Antibody' covid:arg/91e8110a78535c9a7c438219cc93011a17c68c62 named entity 'monoclonal antibodies' named entity 'neutralize' named entity 'Human' named entity 'Coronavirus' named entity 'Characterization' named entity 'MAbs' named entity '15 February' named entity 'Human Monoclonal Antibody' named entity 'light chain' named entity 'MAb' named entity 'transfected' named entity 'pathology' named entity 'Mann-Whitney' named entity 'symptom' named entity 'nmol/L' named entity 'MAbs' named entity 'mice' named entity 'nickel' named entity 'lipofectamine' named entity 'virus' named entity 'lung' named entity 'antibodies' named entity 'MAb' named entity 'histidine' named entity 'MAbs' named entity 'SARS-CoV' named entity 'MAb' named entity 'dose-dependent' named entity 'RSV infection' named entity 'MAb' named entity 'antibody' named entity 'nasal turbinate' named entity 'virus' named entity 'Palivizumab' named entity 'clinical studies' named entity '293T' named entity 'fetal calf serum' named entity 'Palivizumab' named entity 'ACE2' named entity 'public health' named entity 'titer' named entity 'MAb' named entity 'transfected' named entity 'MAb' named entity 'Supernatant' named entity 'nasal turbinate' named entity 'chimeric' named entity 'host cells' named entity 'serum' named entity 'codon' named entity 'neutralizing antibodies' named entity 'SARS-CoV' named entity 'epithelial' named entity 'virus' named entity 'microtiter plates' named entity 'mice' named entity 'effective doses' named entity 'Amersham' named entity '293T' named entity 'MAbs' named entity 'goat' named entity 'mice'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software